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Analysis of Nkx3.1:Cre-driven 
Erk5 deletion reveals a profound 
spinal deformity which is linked to 
increased osteoclast activity
Carolyn J. Loveridge1,2, Rob J. van ’t Hof3, Gemma Charlesworth3, Ayala King1,2, Ee Hong Tan2, 
Lorraine Rose4, Anna Daroszewska3, Amanda Prior3, Imran Ahmad  1,2, Michelle Welsh5, 
Ernest J. Mui2, Catriona Ford2, Mark Salji1,2, Owen Sansom  2, Karen Blyth2 & Hing Y. Leung1,2
Extracellular signal-regulated protein kinase 5 (ERK5) has been implicated during development and 
carcinogenesis. Nkx3.1-mediated Cre expression is a useful strategy to genetically manipulate the 
mouse prostate. While grossly normal at birth, we observed an unexpected phenotype of spinal 
protrusion in Nkx3.1:Cre;Erk5fl/fl (Erk5fl/fl) mice by ~6–8 weeks of age. X-ray, histological and micro CT 
(µCT) analyses showed that 100% of male and female Erk5fl/fl mice had a severely deformed curved 
thoracic spine, with an associated loss of trabecular bone volume. Although sex-specific differences 
were observed, histomorphometry measurements revealed that both bone resorption and bone 
formation parameters were increased in male Erk5fl/fl mice compared to wild type (WT) littermates. 
Osteopenia occurs where the rate of bone resorption exceeds that of bone formation, so we 
investigated the role of the osteoclast compartment. We found that treatment of RANKL-stimulated 
primary bone marrow-derived macrophage (BMDM) cultures with small molecule ERK5 pathway 
inhibitors increased osteoclast numbers. Furthermore, osteoclast numbers and expression of osteoclast 
marker genes were increased in parallel with reduced Erk5 expression in cultures generated from 
Erk5fl/fl mice compared to WT mice. Collectively, these results reveal a novel role for Erk5 during bone 
maturation and homeostasis in vivo.
ERK5 (MAPK7 or BMK) belongs to the family of mitogen-activated protein kinases (MAPKs), members of which 
typically function as signalling nodes to integrate information from extracellular stimuli and different intracel-
lular signalling cascades. Through this activity, MAPKs control numerous biological processes during develop-
ment and homeostasis, including cellular proliferation, differentiation and survival. ERK5 has a uniquely large 
C-terminal domain, which contains nuclear localisation and export signals required for dynamic shuttling of 
ERK5. On the other hand, the N-terminal catalytic domain of ERK5 shares a 50% homology with ERK1/2 and 
inhibitors developed against MEK1/2, such as PD98059 and U0126, have been demonstrated to have off-target 
effects on the MEK5/ERK5 pathway. Unlike other members of the MAPK family, MEK5 is the only MEK (MAPK 
kinase) reported to directly interact with and activate ERK5 via phosphorylation1–3.
Deletion of Mek5 and Erk5 in mice has revealed their essential role during development, where almost iden-
tical phenotypes are observed4–7. Erk5 null mice die around embryonic day 10.5 due to cardiovascular defects 
with impaired vasculogenesis and angiogenesis. This is consistent with findings that ERK5 plays a critical role 
in endothelial cell function8,9. Growth in the head region in these mice was severely retarded. In addition, ERK5 
has been implicated in the physiology of neurones10, muscle11 and immune cells12–14 by controlling prolifera-
tion, differentiation and cell survival. ERK1/2 and ERK5 have distinct roles in the regulation of brain-derived 
neurotrophic factor expression15. In addition to its essential role in development, there is an increasing body of 
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evidence that ERK5 plays a role in tumour development (reviewed in ref.16) and previous work from our labora-
tory has implicated ERK5 as a key driver for prostate carcinogenesis17–19. Hence, we initiated experiments to test 
the impact of in vivo Nkx3.1:Cre-mediated Erk5 deletion in a transgenic mouse model20,21.
Formation of the axial skeleton begins with the subdivision of paraxial mesoderm into somites. Signals (sonic 
hedgehog) emanating from the notochord influence the early somites to form the sclerotome. Sclerotomal cells 
form the beginnings of the vertebrae. Vertebral structures subsequently develop and segment under the influence 
of various cellular signals, including Pax-9 and homeobox-containing genes22–24. A previous study to examine 
the pattern of Nkx3.1 mediated Cre recombinase expression, via the use of ROSA26 reporter mice, documented 
expression of Nkx3.1:Cre in a range of tissues, including somites, dorsal aspects of the spinal ridge, ribs and 
skull25. However, despite expression being noted in somites, no significant skeletal phenotype has been described 
in Nkx3.1 deleted mice to date (reviewed in ref.26).
In this study, our novel finding is that Nkx3.1:Cre driven Erk5 deletion associates with a phenotype of a 
severely curved spine and substantially reduced bone mass/osteopenia. We also report increased osteoclast dif-
ferentiation in primary bone marrow cultures generated from wild type (WT) mice treated with small molecule 
ERK5 pathway inhibitors and in mice with Nkx3.1:Cre-mediated Erk5 deletion compared to WT, indicating a link 
between Erk5 and osteoclast activity in vivo.
Results
Nkx3.1-Cre Erk5 null mice developed severe spinal abnormalities. To circumvent Erk5 null 
induced embryonic lethality, conditional deletion of Erk5 was intended to target the prostate by Cre recom-
binase inserted into the Nkx3.1 locus. However, we observed marked phenotypic abnormalities in male and 
female Nkx3.1:Cre;Erk5fl/fl mice (homozygous for the Erk5 conditional allele), referred to hereafter as Erk5fl/fl  
mice. Newborn pups all had the same normal gross morphology, regardless of genotype, but by 10–12 weeks 
of age, Erk5fl/fl male and female mice were noticeably and significantly smaller in size compared to WT 
[Nkx3.1:Cre;Erk5+/+ or mice which did not express Cre recombinase] and Erk5fl/+ [heterozygous for the Erk5 
conditional allele; Nkx3.1:Cre;Erk5fl/+] littermate controls (Fig. 1A and S1A and Tables S1 and S2). Erk5fl/fl male 
and female mice, from ~6–8 weeks onwards, exhibited a protruding spine when compared to WT and Erk5fl/+ 
littermate controls (Fig. 1A), indicative of a potential underlying bone defect causing abnormal curvature of the 
thoracic spine. Overall, among 33 Erk5fl/fl mice (17 male and 16 female), all developed a spinal phenotype. In 
contrast, 17 (7 male and 10 female) Erk5fl/+ and 42 (18 male and 24 female) WT littermate control mice did not 
demonstrate any clinical evidence of spinal defect. Moreover, a curled tail phenotype (Fig. 1B) was observed in 
~30% Erk5fl/fl mice (5/17 males and 5/16 females; > 6 weeks old). There was no evidence of abnormalities in other 
major organs examined, including the prostates of Erk5fl/fl male mice (Fig. S1B).
X-ray analysis of whole body and isolated spines from 7 and 10–12 week old WT, Erk5fl/+ and Erk5fl/fl male 
and female mice showed no major differences between Erk5fl/+ and WT mice (Fig. 1C and D). In contrast, we 
observed severe spinal curvature in the thoracic region of male and female Erk5fl/fl mice at 7 weeks (Fig. 1E) and 
10–12 weeks of age (Fig. 1C and D), regardless of curled tail phenotype. Micro-computed tomography (μCT) 
analysis of newborn pups (2 days after birth) demonstrated that there was no spinal defect present in Erk5fl/fl mice 
compared to WT littermates (Fig. 1F), suggesting that the defect manifests during post-embryonic skeletal mat-
uration. μCT analysis of isolated spines from older (10–12 weeks) male (Fig. 1G) and female (Fig. S1D) Erk5fl/fl 
mice confirmed the marked curvature in the spine as seen in plain X-ray imaging. The affected vertebrae in male 
and female Erk5fl/fl mice showed striking wedge-shaped deformities, indicative of vertebral collapse, as can be 
seen from the detailed images of WT and Erk5fl/fl spines in the bottom panels of Fig. 1G and S1D. No spinal phe-
notype was observed in Nkx3.1Cre/Cre;Erk5+/+ mice, which were homozygous for the Nkx3.1:Cre allele (Fig. S1C). 
Collectively, these data suggest that the loss of Erk5, rather than Nkx3.1-driven Cre expression, is the causative 
event for the spinal phenotype.
Trabecular bone loss in Erk5fl/fl mice. Histological analysis of the thoracic spine confirmed the deforma-
tion of the thoracic vertebrae in Erk5fl/fl mice compared to WT mice (compare 4x images in Fig. 2A). Moreover, 
the vertebrae in the affected region from Erk5fl/fl mice were variably larger in size and structurally dis-organised 
when compared to WT control mice. Vertebrae from Erk5fl/fl mice were characterized by a significant increase 
in marrow space in association with a profound loss of trabecular bone mass (compare 10x and 20x images in 
Fig. 2A). The spinal cords showed no gross pathology associated with compression but inter-vertebral discs were 
enlarged with some structural malformation of nucleus pulposus (NP) tissue between collapsed thoracic ver-
tebrae in Erk5fl/fl mice compared to WT mice. However, it is noteworthy that the inter-vertebral disc NP tissue 
located between thoracic vertebrae that had not collapsed in Erk5fl/fl mice appeared similar to WT (Fig. S1E).
The severe deformation of the thoracic vertebrae would make a quantitative analysis of the bone architecture 
difficult to interpret. Therefore μCT analysis of bone architecture was performed using the 5th lumbar vertebrae 
(L5) because generally, these were not badly deformed. High-resolution μCT analysis of L5 isolated from WT, 
Erk5fl/+ and Erk5fl/fl mice (Fig. 2B) demonstrated a dramatic loss of bone volume in Erk5fl/fl male and female 
mice when compared to WT. Although the lumbar vertebrae showed no major deformation overall, some minor 
changes to the end plates and the central canal were observed (highlighted by yellow arrows). Both male and 
female Erk5fl/fl mice showed substantial loss of trabecular bone volume (Fig. 2B and C and Table S3). The bone 
loss was more pronounced in male Erk5fl/fl mice, where a 54% decrease in bone volume per tissue volume (BV/
TV) was seen compared to WT. Female Erk5fl/fl mice showed a lower, but still substantial 35% decrease in BV/TV 
compared to WT. The loss of trabecular bone volume was accompanied by a significant reduction in trabecular 
number (Tb.N) in both male (54.1% compared to WT) and female (39% compared to WT) Erk5fl/fl mice. There 
was no significant difference in trabecular thickness (Tb.Th) in male and female Erk5fl/fl mice compared to WT. 
However, a deterioration of bone architecture was observed, as indicated by decreased trabecular connectivity 
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Figure 1. Erk5fl/fl mice exhibit spinal protrusion, curled tail and have severe spinal deformities in the thoracic 
region. (A) Compared to WT and Erk5fl/+ littermates, a protruding spine in Erk5fl/fl mice was evident in Erk5fl/fl mice 
(yellow arrow). (B) Curled tail was apparent in a proportion of male and female Erk5fl/fl mice. The image shown is of 
a 4.5 month old male. (C) Representative images of whole body X-rays of 11 week old female mice. Severely curved 
spine is evident in Erk5fl/fl mouse compared to WT and Erk5fl/fl mice, where no spinal deformity was seen. Yellow 
arrows highlight the main areas of deformity in the thoracic region of the spine. (D) Representative images showing 
longitudinal view of X-rays of isolated spines from 10–12 week old male mice. No spinal deformity was seen in WT 
or Erk5fl/+ mice. As was observed in Erk5fl/fl female mice, a severely curved spine was apparent in Erk5fl/fl male mice. 
Yellow arrows highlight the main areas of the deformity in the thoracic region of the spine. (E) Representative images 
showing longitudinal view of X-rays of isolated spines from 7 week old male and female Erk5fl/+ and Erk5fl/fl mice. 
Similar to 10–12 week old mice, severely curved spines were apparent in male and female Erk5fl/fl mice at 7 weeks of 
age. (F) Representative images of low resolution µCT of newborn pups. No spinal defect was found in Erk5fl/fl mice at 
this stage of development. (G) Representative images of low resolution µCT of isolated spines from male Erk5fl/fl mice. 
In the bottom panel, fine detail images of male spines are shown. Yellow arrows denote deformation of the mutant 
spinal column. Note the wedge-shaped deformation of the mutant vertebral body in the fine detail view shown in the 
lower panel. Red boxes in the top panel indicate the regions of the spines shown in finer detail in the bottom panel.
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Figure 2. Erk5fl/fl mice lack trabecular bone structure and have reduced bone volume. (A) Representative 
micrographs (4 × 10x and 20x) of H + E staining of longitudinal sections from vertebrae of 5 month old female 
WT and Erk5fl/fl mice. Black arrow indicates trabecular structure, which is clearly reduced in Erk5fl/fl  
mice compared to WT. Abbreviations: BM = bone marrow; GP = growth plate; IVD = inter-vertebral disc; 
MS = medulla spinalis; NP = nucleus pulposus; TB = trabecular bone; VB = vertebrae. (B) Representative 
images of high resolution µCT analysis of L5 vertebrae from 11 week old male and female WT and Erk5fl/fl mice. 
Shown in top panel are lateral views; shown in bottom panel are transverse views. Yellow arrows denote some 
deformation of the end plates (top panel) and narrowing of the central canal in virtually cut (bottom panel) 
mutant vertebrae. (C) Quantitative analysis of high resolution µCT parameters indicate a significant reduction 
in trabecular BV/TV (%) and Tb.N (mm−1) in male and female Erk5fl/fl mice compared to WT and a significant 
increase in SMI in male and female Erk5fl/fl mice compared to WT. Abbreviations: BV/TV: bone volume per 
tissue volume; Tb.Th: trabecular thickness; Tb.SP: trabecular separation; Tb.N: trabecular number; SMI: 
structure model index. Shown in the graphs are means; error bars represent SEM; t test (unpaired, 2 tailed) was 
used to calculate p values and those with significance are shown. *p < 0.05; **p < 0.01 from same sex wild type.
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and a significant increase in the structure model index (SMI) in both male and female Erk5fl/fl mice compared 
to WT. Erk5fl/+ male mice also displayed reduced bone volume (15%) and trabecular number (15.8%) compared 
to WT, but this was less severe than Erk5fl/fl, indicating the possibility of a dosage-dependent effect of Erk5 loss.
To address whether bone abnormalities were present in the appendicular skeleton in addition to the axial 
skeleton, we analysed distal femurs by μCT (Fig. S2A and B and Table S4). There was a substantial decrease in 
BV/TV in both Erk5fl/fl and Erk5fl/+ males (44% and 24% respectively) compared to WT. Female Erk5fl/fl mice also 
demonstrated significantly reduced BV/TV (23%) compared to WT, although this was not as marked as in the 
Erk5fl/fl male mice. Erk5fl/+ females showed no significant bone loss in the distal femur. In keeping with trends 
seen for the spine, changes in bone architecture were observed in the distal femurs of male and female Erk5fl/fl 
mice. Specifically, there was a significant reduction in Tb.Th and a significant increase in trabecular pattern factor 
(Tb.Pf) in both male and female Erk5fl/fl mice compared to WT. In both Erk5fl/+ and Erk5fl/fl males, there was a sig-
nificant reduction in Tb.N and increase in trabecular separation (Tb.Sp) compared to WT but these parameters 
were not changed in female Erk5fl/+ or Erk5fl/fl mice. It is noteworthy that the overall shape and morphology of the 
long bones of Erk5fl/fl mice appeared similar to WT and the growth plate in distal femurs of male Erk5fl/fl mice had 
no significant abnormalities (Fig. S2C), indicating that there was no major defect with endochondral ossification.
Analysis of bone turnover in Erk5fl/fl mice. Bone homeostasis is achieved via the controlled activities 
of two major cell types: osteoblasts synthesize and deposit new bone matrix while osteoclasts break down and 
resorb bone. The bone loss observed in the Erk5fl/fl mice could therefore be due to a decrease in bone formation, 
an increase in bone resorption or a combination of both. In order to address this question, we performed dynamic 
histomorphometry on L5 vertebrae of 10–12 week old mice. In Erk5fl/fl males, the histomorphometry showed a sig-
nificant 69% increase in osteoclast surface (Oc.S) and a 68% increase in osteoclast number (N.Oc) per bone surface 
(BS) (N.Oc/BS) (Fig. 3B) as assessed by tartrate-resistant acid phosphatase (TRAP) staining (Fig. 3A). There was 
a non-significant trend for increased osteoclast surface and a significant increase in osteoclast number in Erk5fl/+ 
males, again indicating the possibility of a dosage-dependent effect of Erk5 loss (Fig. 3B and Table S5). There was 
no statistically significant increase in bone resorption parameters in Erk5fl/+ or Erk5fl/fl female mice. Calcein double 
labels were used to assess bone formation parameters. While there was no difference in mineral apposition rate, we 
observed a significant increase in mineralizing surface per bone surface (MS/BS) and bone formation rate per bone 
surface (BFR/BS) in Erk5fl/fl males compared to WT. There was no significant difference in any bone formation 
parameters in Erk5fl/+ males or Erk5fl/+ or Erk5fl/fl female mice compared to WT controls (Table S5).
Collectively, data from histomorphometry analysis are consistent with the observed bone loss in the vertebrae 
of Erk5fl/fl mice being associated with increased osteoclast activity. Key mediators of osteoclastogenesis include 
the receptor activator of NF-κB ligand (RANKL) and its negative regulator, osteoprotegerin (OPG). We measured 
the serum levels of these secreted factors in WT and Erk5fl/fl male mice (7–11 weeks of age). There was a signif-
icant decrease in serum RANKL levels and a significant increase in serum OPG levels, resulting in a significant 
decrease in the ratio of RANKL to OPG from 0.164 in WT to 0.047 in Erk5fl/fl male mice (p = 0.007) (Fig. 3C). It 
is possible that the loss of bone mass in Erk5fl/fl mice may have resulted in the activation of compensatory mecha-
nisms, such as the increased production of OPG and decreased production of RANKL.
Reduction of Erk5 expression increased osteoclast numbers and expression of Rank, 
Cathepsin K (Ctsk) and Nuclear factor of activated T-cells (Nfatc1) in osteoclasts derived from 
Erk5fl/fl mice. To further investigate the involvement of Erk5 in the osteoclast compartment, macrophage 
colony-stimulating factor (M-CSF) dependent bone marrow-derived macrophages (BMDMs, osteoclast line-
age pre-cursors) and osteoclasts (RANKL-stimulated BMDMs) were generated from the long bones of WT and 
Erk5fl/fl mice. Quantitative PCR (QPCR) was performed using RNA extracted from these BMDM and osteoclast 
cultures. BMDM and osteoclast cultures derived from Erk5fl/fl mice exhibited significantly lower expression of 
Erk5 Exon 4 (the floxed region) when compared to WT controls (Fig. 4A and B), in keeping with an Nkx3.1:Cre 
mediated event. Moreover, BMDM cultures generated from Erk5fl/fl mice had significantly reduced levels of ERK5 
protein compared to WT controls as assessed by Western blot (Fig. 4B and S3). To confirm reduced expression 
of Erk5 in vertebral tissue sections, we tried immunohistochemical and in situ hybridization, by RNA Scope, 
staining of vertebral tissue sections for ERK5 protein and Erk5 mRNA transcripts respectively but this was 
unsuccessful. To demonstrate successful areas of Cre recombination, a proportion of mice were bred to carry 
the Z/EGFP reporter transgene27. The Z/EGFP reporter mouse expresses lacZ throughout all embryonic and 
adult developmental stages. The expression of Nkx3.1:Cre during development leads to the excision of the lacZ 
gene, allowing expression of the second reporter, EGFP and so this essentially acts as a surrogate marker of 
Cre expression. GFP was found to be expressed in the macrophage and osteoclast cultures (Figure S2D) gen-
erated from Nkx3.1:Cre-expressing, Z/EGFP +ve mice, indicating the expression of Cre in the bone. RANKL 
dose-response experiments showed significantly increased numbers of osteoclasts in Erk5fl/fl cultures versus WT 
at concentrations of 10 ng/mL RANKL and above (Fig. 4C). Furthermore, the MEK5 inhibitors BIX02188 and 
BIX02189 stimulated RANKL-induced osteoclast formation in cultures from WT mice (Fig. 4D), suggesting that 
Erk5 negatively regulates osteoclast differentiation. Next, we characterized the expression of a panel of osteoclast 
markers. Consistent with enhanced osteoclast differentiation, we found a significant increase in the expression of 
Rank (the receptor for RANKL), Ctsk (the gene encoding cathepsin K, the protease released by osteoclasts during 
bone resorption) and Nfatc1 (a transcription factor that is crucial for osteoclast differentiation) in Erk5fl/fl cultures 
versus WT (Fig. 4E). Collectively, these data demonstrate that reduction of Erk5 expression in the osteoclast com-
partment correlates with increased osteoclastogenesis and function.
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Figure 3. Bone histomorphometry in L5 vertebrae demonstrates increased osteoclast activity and increased bone 
formation parameters in male Erk5fl/fl mice. (A) Representative micrographs of TRAP staining in L5 vertebrae of 
11 week old male and female WT and Erk5fl/fl. Black arrows indicate TRAP-stained osteoclasts (stained in red). 
Bone tissue was counterstained with Aniline Blue. Red boxes in low magnification images in the left panel indicate 
the regions shown at higher magnification in the right panel. (B) Quantitative analysis of bone histomorphometry 
parameters, as assessed from TRAP staining and calcein double labelling experiments, demonstrate significantly 
reduced BV/TV (%) in both male and female Erk5fl/fl mice compared to WT. In male Erk5fl/fl mice, Oc.S/BS (%), 
N.Oc/BS (mm−1) and the bone formation parameters, MS/BS (%) and BFR/BS were significantly increased 
compared to WT littermates. There were no significant differences found in bone resorption or formation parameters 
in female mice. Abbreviations: BV/TV: bone volume per tissue volume; Oc.S/BS: osteoclast surface per bone surface; 
N.Oc/BS: number of osteoclasts per bone surface; MAR: mineral acquisition rate; MS/BS: mineralising surface per 
bone surface; BFR/BS: bone formation rate per bone surface. Shown in the graphs are means; error bars represent 
SEM; t test (unpaired, 2 tailed) was used to calculate p values and those with significance are shown. *p < 0.05; 
**p < 0.01; ***p < 0.001 from same sex wild type. (C) Ratio of RANKL/OPG is significantly reduced in Erk5fl/fl  
mice compared to WT. Serum RANKL and OPG levels were measured in 7–11 week old male WT (n = 4) and 
Erk5fl/fl mice (n = 3) by ELISA [expressed in nanograms per millilitre (ng/mL)] and the ratio of RANKL/OPG was 
subsequently calculated. Shown in the graphs are means; error bars represent SEM; t test (unpaired, 2 tailed) was used 
to calculate p values and those with significance are shown. *p < 0.05; **p < 0.01; ***p < 0.001 from same sex WT.
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Figure 4. Erk5 expression is significantly reduced in BMDM and mature osteoclast cultures from Erk5fl/fl  
mice compared to WT in parallel with a significant increase in osteoclast numbers and expression of the 
osteoclast markers, Rank, Ctsk and Nfatc1. (A) QPCR analysis of Erk5 (Exon 4) mRNA expression (normalised 
to housekeeping gene, Hmbs) in BMDM and osteoclast cultures generated from Erk5fl/fl and WT mice. Shown 
are means; error bars represent SEM; t test (unpaired, 2 tailed) was used to calculate p values and those with 
significance are shown. *p < 0.05 from WT. (B) Western blot analysis (Left panel) of total ERK5 protein 
expression in BMDM cultures derived from WT (n = 5) and Erk5fl/fl (n = 5) mice. Black box highlights 
colorimetric image of molecular weight markers which was overlaid with chemiluminescent image of samples 
to confirm the size of observed bands. Full images are shown in Fig. S3. Densitometry analysis (right panel) was 
performed using image J to normalise total ERK5 levels to those of the housekeeping gene, HSC70. Shown are 
mean normalised expression levels of ERK5 for WT and Erk5fl/fl; error bars represent SEM; t test (unpaired, 2 
tailed) was used to calculate p values and those with significance are shown. *p < 0.05 from WT. (C) Osteoclast 
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Discussion
While investigating the role of Erk5 in the prostate using Nkx3.1-Cre recombinase expression, we observed a 
novel, dramatic spinal deformity in Erk5fl/fl mice. Erk5fl/fl mice were phenotypically normal at birth but developed 
the spinal defect by 2 months of age, suggesting that the loss of Erk5 during the process of post-natal skeletal 
maturation is associated with the observed spinal phenotype. The spinal deformity was found to be linked with 
a profound reduction of trabecular bone mass in the vertebral column of both male and female Erk5fl/fl mice. 
From histomorphometry studies, we found that the low bone mass in male Erk5fl/fl mice was associated with 
increased bone-remodeling, with both significantly enhanced bone resorption and bone formation parameters 
being observed. It was striking that almost all (~90%) of the entire bone surface was undergoing re-modelling, 
either resorption or bone formation, in male Erk5fl/fl mice.
Low bone mass (osteopenia/osteoporosis) occurs when bone turnover is imbalanced in favour of bone resorp-
tion i.e. where the rate of bone resorption by osteoclasts exceeds the rate of bone formation by osteoblasts. Our 
dynamic histomorphometry data in male Erk5fl/fl mice point towards dis-regulated osteoclast function upon loss 
of Erk5 as being the primary cause for the observed bone loss. However, we did not observe increased osteoclast 
surface or number in Erk5fl/fl female mice and the loss of bone mass was greater in male compared to female Erk5fl/fl 
mice, indicating that there are sex-specific differences. Gonadal sex steroid hormones (androgens and estrogens) 
are known to play an important role in bone homeostasis28,29. In particular, estrogen is known to inhibit osteo-
clastogenesis and osteoblast apoptosis30. Osteoporosis is a common disease in post-menopausal women, when 
estrogen levels have declined. It is established that while there is a net loss of bone mass, both bone resorption and 
bone formation rates are elevated in post-menopausal osteoporosis31, which is in keeping with our observations 
in male Erk5fl/fl mice. The spinal deformity develops in Erk5fl/fl female mice during the first two months of life and 
we suggest that the presence of estrogen in the female Erk5fl/fl mice at the time when bone histomorphometry 
parameters were assessed (10 weeks) mediates a protective effect in terms of inhibiting osteoclastogenesis/bone 
resorption and reducing the elevated bone formation rate when compared to male Erk5fl/fl mice. Testosterone 
levels in male Erk5fl/fl mice were found to be normal (data not shown) but future studies, beyond the scope of this 
work, to determine whether estrogen treatment could have a protective effect in the male Erk5fl/fl mice would be 
interesting and informative.
Development and maintenance of bone tissue involves precise spatial and temporal interplay between osteo-
clast and osteoblast function. RANKL is a key regulator of osteoclastogenesis and is negatively regulated by OPG. 
It is increasingly apparent that the major sources of both of these factors are osteoblasts and osteocytes, highlight-
ing an important interplay between bone formation and bone resorption32,33. Our gross observations of the phe-
notype and extent of spinal deformity in Erk5fl/fl mice are similar to those from a classical study of osteoprotegrin 
(OPG)-deficient mice34, where it was reported that while embryonic bone formation appeared normal, adolescent 
and adult OPG-deficient mice exhibited a marked decrease in total bone density and trabecular bone porosity. 
Furthermore, the OPG-deficient mice also presented with curvature of the spine, had an increased incidence of 
vertebral bone fractures in the first two months of age and exhibited very active bone re-modeling, with increases 
in both osteoclast and osteoblast surface per bone surface. We examined the serum levels of RANKL and OPG in 
7–11 week old WT and Erk5fl/fl male mice by ELISA and found that at this age, there was a significant reduction in 
the ratio of RANKL to OPG in Erk5fl/fl mice compared to WT, which would normally result in lower bone resorp-
tion levels. Although the RANKL/OPG ratio is very important for the maintenance of bone homeostasis, our 
results indicate that changes in this ratio are not what drives the low bone mass phenotype in these mice. Rather, 
this phenotype is most likely driven by increased responsiveness of the osteoclast precursors to RANKL, as sug-
gested from our primary BMDM culture studies using a RANKL dose-response curve. The resulting increase in 
osteoclast formation could lead to bone loss in vivo, and this bone loss may result in the activation of compensa-
tory mechanisms, such as the increased production of OPG and decreased RANKL production. Increased serum 
OPG levels have been observed in cases of post-menopausal osteoporosis35.
It is of interest that while Erk5 has not been implicated in genome-wide association studies (GWAS) in the 
osteoporosis field to date36, a network-based meta analysis of gene expression profiles in women with bone 
mineral variations identified Mekk3 (Mek kinase 3), which encodes an upstream kinase of MEK5 in the ERK5 
pathway, as one of five candidate genes to be associated with bone mineral density37. Furthermore, Mekk3 was 
identified as being induced by M-CSF in an oligonucleotide microarray study of gene expression patterns in 
mouse bone marrow mononuclear cells during the process of osteoclast differentiation38. Another upstream 
kinase of MEK5 in the ERK5 pathway, Mekk2, has previously been shown to be important in the regulation of 
formation is increased in RANKL-stimulated BMDM cultures derived from Erk5fl/fl mice compared to WT. 
Figure shown is combined data from 3 independent experiments; n = 5 for each concentration of RANKL used 
within each experiment. Data was normalised to and is expressed as % of WT treated with 100 ng/mL RANKL. 
Shown are means; error bars represent SEM; ANOVA was used to calculate p values and those with significance 
are shown. **p < 0.01 from WT. (D) MEK5 inhibitors BIX02188 and BIX02189 (100 nM) stimulate osteoclast 
formation in WT cultures. Figure shown is combined data from 3 independent experiments; n = 5 for vehicle 
and each inhibitor used within each experiment. Data was normalised to and is expressed as % of vehicle 
control. Shown are means; error bars represent SEM; ANOVA was used to calculate p values and those with 
significance are shown. **p < 0.01 from vehicle. (E) QPCR analysis of Rank, Ctsk and Nfatc1 mRNA expression 
(normalised to housekeeping gene, Hmbs) in BMDM and osteoclast cultures generated from Erk5fl/fl (n = 4) and 
WT (n = 3) mice. Shown are means; error bars represent SEM; t test (unpaired, 2 tailed) was used to calculate p 
values and those with significance are shown. *p < 0.05; **p < 0.05, ****p < 0.0001 from WT.
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 13241  | DOI:10.1038/s41598-017-13346-8
osteoblast activity39. Collectively, our data are in keeping with a role for ERK5 pathway in normal bone homeo-
stasis and clinically relevant osteoporosis.
Besides the spine, μCT of the long bones in the hind limbs also revealed significant loss of bone mass and 
trabecular structure in the Erk5fl/fl mice, indicating that there are effects in the appendicular skeleton as a result 
of Nkx3.1-mediated Cre recombinase expression. Our finding that Erk5 expression is reduced in BMDM and 
osteoclast cultures support the notion of an impact of loss of Erk5 in the appendicular skeleton. Examination 
of the growth plate from µCT images of distal femurs revealed that there was no major defect in growth plate 
cartilage/endochondral ossification, in male Erk5fl/fl mice compared to WT. However, the mineralised cartilage 
area appeared to be thinner, most probably due to the increased osteoclast activity in these mice. The additional 
phenotype of curly tail in a proportion of Erk5fl/fl mice is intriguing, and may result from the spine defect, similar 
to those seen in mouse models for spina bifida, neural tube defects and other transgenic mouse models40,41.
Importantly, we demonstrated that GFP, a surrogate marker for Nkx3.1:Cre activity, was expressed in BMDM 
and osteoclast cultures generated from Nkx3.1:Cre-expressing, Z/EGFP + ve mice. In parallel, Erk5 mRNA 
expression was significantly reduced in BMDM and osteoclast cultures and total ERK5 protein expression was 
significantly reduced in BMDM cultures generated from Erk5fl/fl mice compared to WT, which is in keeping with 
Cre-mediated recombination having occurred. The efficiency of Cre-mediated recombination is never 100% and 
so our observed partial reduction in Erk5 expression is indicative that deletion is occurring in only a subset of the 
cells. Despite this, osteoclast numbers and expression of osteoclast differentiation markers including Rank, Ctsk 
and Nfatc1 were significantly increased in BMDM and osteoclast cultures generated from Erk5fl/fl mice compared 
to WT. As further validation of our findings in Erk5fl/fl cultures, we also demonstrated that inhibition of ERK5 
pathway via treatment with the MEK5 inhibitors, BIX02188 and BIX02189, significantly increased osteoclast 
numbers in cultures generated from WT mice. Collectively, these data indicate that reduction of Erk5 expression 
or activity in osteoclast pre-cursors is associated with increased osteoclastogenesis.
While our data indicate the osteoclast as being the primary compartment responsible for the observed 
bone loss, it is possible that other cell types could be affected by loss of Erk5 expression driven by Nkx3.1-Cre. 
Interestingly, a recent study demonstrated that ERK5 is implicated in degenerated human intervertebral disc NP 
tissues42. ERK5 expression was found to be reduced in degenerated compared to normal tissues and treatment 
with TNF-α, which is implicated in NP cell degeneration, reduced Erk5 mRNA expression and the expression of 
NP cell marker genes. In our study, the NP tissue between collapsed thoracic vertebrae in Erk5fl/fl mice was found 
to have an abnormal, distorted appearance whereas NP tissue located between thoracic vertebrae that had not 
collapsed in Erk5fl/fl mice appeared similar to WT. Furthermore, our histomorphometry studies were performed 
in lumbar vertebrae that showed no major deformation in intervertebral NP tissue, yet these vertebrae still show 
increased bone resorption. We suggest, therefore, that the NP deformation most likely results from vertebral 
collapse. Future studies to target Erk5 ablation using an osteoclast-specific Cre, such as Ctsk-Cre, or other cell 
lineage-specific-Cre would be very informative to further address the question of the causal relationship between 
loss of Erk5 in the osteoclast compartment with the spinal deformity.
To date, in vitro investigations of ERK5 in osteoblast and osteoclast biology have produced conflicting find-
ings with both differentiation promoting and suppressive effects being documented43–46. Cyclic fluid shear stress 
has been shown to stimulate the proliferation of osteoblasts via an ERK5 signalling pathway43,44. However, in 
contrast to those studies, it has also been reported that the expression of key phenotypic markers for osteoblast 
differentiation, osteocalcin, alkaline phosphatase and osterix, are reduced after treatment with the MEK5 inhib-
itor, BIX02189, suggesting that MEK5 can suppress osteoblast differentiation45. Our data are in keeping with the 
former studies as we observe increased bone formation parameters in male Erk5fl/fl mice although we suggest that 
this could be an indirect effect of enhanced osteoclast activity. A very recent study has shown that ERK5 activa-
tion, through the induction of c-Fos, is essential for osteoclast-like differentiation of the monocytic RAW264.7D 
clone and 4B12 cells in response to RANKL and RANKL + M-CSF respectively46. The findings of Amano et al. are 
in contrast to our report as we demonstrate that reduction of Erk5 expression, in the case of Erk5fl/fl mice, or inhi-
bition of ERK5 pathway, in the case of treatment with small molecule MEK5 inhibitors, associated with increased 
osteoclast numbers and expression of osteoclast differentiation markers. Besides using primary bone marrow 
cells from our in vivo mouse model as opposed to cell lines, the ERK5 pathway inhibitor concentrations we used 
were considerably lower than those used by Amano et al. (100 nM versus 1–8 µM) because at high concentration 
of these inhibitors, we observed a high degree of toxicity and it is likely that selectivity for MEK5 is lost given that 
the reported IC50 for MEK5 kinase inhibition is 1.5 nM for both BIX0218 and BIX02189. Furthermore, Amano et 
al. used the inhibitor, XMD8-92, which is now known to have off-target effects against bromo domain-containing 
proteins47. For the first time, our study sheds important insights into the functional role of ERK5 in bone biology 
in an in vivo model.
In conclusion, we demonstrate an important role of Erk5 in bone development and homeostasis in vivo. 
Loss of Erk5 driven by Nkx3.1-Cre associated with a severe spinal deformity and an osteopenic phenotype. 
Furthermore, our evidence indicates that reduction of ERK5 pathway activity and Erk5 gene expression promotes 
osteoclastogenesis. Our model could be of benefit to further our knowledge and understanding of the molecular 
events regulating bone homeostasis, spinal deformities and/or osteopenia.
Materials and Methods
Mouse Strains and Breeding. All small animal (murine) experiments were (i) approved by the Animal 
Welfare and Ethical Review Board (AWERB) at the University of Glasgow and (ii) performed in accordance 
with relevant guidelines and regulations. Nkx3.1:Cre mice48 were intercrossed with mice harbouring the con-
ditional inactivatable Erk5 allele (where Exon 4 is flanked by LoxP sites)49 to generate Nkx3.1:Cre;Erk5fl/+ and 
Nkx3.1:Cre;Erk5fl/fl mice. A proportion of these mice were interbred with mice containing the Z/EGFP reporter 
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transgene27. This transgene results in the expression of β-galactosidase in most tissues. The β-geo insert of the 
transgene is flanked by lox p sites and the expression of Cre recombinase results in the excision of the β-geo 
insert, activating the constitutive expression of GFP where Cre is expressed. Mice were genotyped by PCR by 
TransnetyxTM. Mice were of a mixed background (C57BL/6J) with strain-matched littermates (either Cre+ve WT 
or mice not expressing Cre) used as control mice.
Radiography. Whole body radiographs and radiographs of isolated spines of transgenic animals after sacri-
fice were performed using the Siemens Angiographie (AX) system. Exposure factors were: 40 kV; 50 mAs; 115 cm 
film to focus distance (FFD). Agfa CR 35-X developing cassettes were used.
Histological Analysis. For histological analysis, mice were sacrificed using CO2 narcosis in order to main-
tain an intact skeleton, then bone tissues and a spectrum of other tissues, including liver, lung, kidney, heart, 
pancreas, prostate, leg muscle and small intestine, were collected and fixed intact in 10% formalin for 24 hr and 
subsequently processed for paraffin embedding. Sections from these paraffin blocks were stained with haematox-
ylin and eosin (H + E).
μCT analysis. Whole mouse spines and 2-day-old pups were imaged using a Skyscan1076 in vivo μCT scan-
ner (Skyscan, Kontich, Belgium) and were scanned at a resolution of 18 μm, with a source voltage of 50 kV, a 0.6° 
rotation step and a 0.5 mm aluminium filter. The scans were reconstructed using NRecon software, and visualised 
using CTVox and Dataviewer software (all Skyscan).
High resolution scans of mouse lumbar vertebrae and distal femurs were obtained using a Skyscan 1272 sys-
tem at 4.5 μm resolution, 50 kV source voltage, 0.5° rotation step and a 0.5 mm aluminium filter. Scans were 
visualised as described above, and analysed using CtAn software (Skyscan). For the 5th lumbar vertebrae, the 
bone parameters were measured in the vertebral body, excluding the cortex and the end plates. For the distal 
femur, the analysis was performed in 200 slices 0.1 mm proximal of the primary spongiosa.
Bone Histomorphometry. The mice received two injections of calcein (200 µl IP injection of 2 mg/ml) 
at 5 and 2 days before culling. Specimens were then fixed in 10% buffered formalin for 24 hr, and stored in 70% 
ethanol. After uCT analysis, the samples were dehydrated through an alcohol series, cleared in xylene, embedded 
in methyl methacrylate, and 5 μm sections were cut on a Leica RM2265 microtome.
For analysis of bone resorption parameters, the specimens were stained for TRAP to identify osteoclasts and 
the bone counterstained using Aniline Blue as described by Chappard et al.50. The sections were imaged on a Zeiss 
Axioimager microscope with a 10x lens and a QImaging Retiga 4000 camera resulting in a pixel size of 1.487 μm.
For analysis of bone formation parameters, the sections were stained without deplastification for 3 min in 
0.1% Calcein Blue (Sigma), pH 8. The sections were washed twice in water, dehydrated through an alcohol series, 
cleared in xylene and coverslipped using Eukit (Sigma). The mineralised bone was imaged using a DAPI filter set, 
and the calcein labels using an FITC filter set on a Zeiss Axioimager microscope with a 20x lens and a QImaging 
Retiga 4000 camera resulting in a pixel size of 0.372 μm.
Bone histomorphometric analysis was performed using a custom in-house developed image analysis program 
based on ImageJ, available at https://www.liverpool.ac.uk/ageing-and-chronic-disease/bone-hist/ 51.
RNA Isolation and Quantitation. RNA was isolated using RNeasy Mini Kit (Qiagen) as per manufacturer’s 
instructions, including a DNAse digestion step. RNA samples were quantified either by Qbit Assay (Invitrogen) 
according to manufacturer’s instructions or using a NanoDrop™ spectrophotometer (Thermo Scientific).
Quantitative Real Time Polymerase Chain Reaction (QPCR) – Taqman. cDNA was prepared from 
RNA samples using High Capacity cDNA Transcription Kit (Applied Biosystems). QPCR was performed to eval-
uate relative transcript expression levels in cDNA samples using the Taqman technique. Specific primer/probe 
combinations (Table S6) and Taqman Universal PCR Mastermix (Applied Biosystems) were added to cDNA sam-
ples (according to manufacturer’s instructions) before being run on an Applied Biosystems 7500 Fast Real-Time 
PCR System machine. The QPCR conditions were: 20 sec at 50 °C, 10 min at 95 °C, followed by 40 cycles of 15 sec 
at 95 °C and 1 min at 60 °C. Technical replicates for each sample and a minimum of three independent samples 
for each genotype/cell line were included. Hmbs, the gene encoding hydroxymethylbilane synthase, was used as 
the ‘house-keeping’ or reference gene and 7500 Software v2.0.5 (Applied Biosystems) used 2−ΔΔCT method to 
determine the relative gene expression. Primer/Probe sets were designed using the Universal Probe Library (UPL) 
Assay design centre (Roche).
Enzyme-linked immunosorbent assay (ELISA). Serum samples were collected from mouse whole 
blood by centrifugation for 15 min at approximately 800 × g. We used the RANKL (TNFSF11) Mouse ELISA Kit 
(ab100749) and Osteoprotegerin Mouse ELISA Kit (ab100733) (ELISA) from Abcam® (Cambridge, UK) to meas-
ure the serum levels of RANKL and OPG in 7–11 week old male WT and Erk5fl/fl mice, according to manufactur-
er’s instructions. Serum samples were diluted 1:15 for RANKL ELISA and 1:50 for OPG ELISA using Diluent A 
which was provided with the kits. Standard curves and experimental samples were performed in duplicates. Data 
are expressed as nanograms per milliliter.
Generation and culture of BMDMs and osteoclasts. Bone marrow cells were flushed out of the long 
bones of the mice and the cell suspension cultured in αMEM supplemented with 10% FCS, Pen/Strep and 100 
ng/ml M-CSF (Prospec Bio) for three days. Next the non-adherent cells were removed by washing the cultures 
with PBS, and the adherent BMDMs harvested using Acutase (Sigma) or cell dissociation buffer (Enzyme-Free; 
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PBS-based) (Gibco, Life Technologies). For osteoclast formation experiments, cells were plated in 96-well plates 
at 15 × 103 cells in 100 µl medium supplemented with 25 ng/ml M-CSF and up to 100 ng/ml RANKL (a kind gift 
of Dr. J. Dunford, University of Oxford) per well. The culture medium was refreshed at day 2 and day 4 and the 
cells fixed on day 5 with 4% buffered formalin and stained for TRAP. TRAP positive cells containing three or more 
nuclei were counted as osteoclasts. For RNA isolation, BMDM cells were seeded in 6-well plates at 5 × 105 cells 
per well in medium supplemented with 25 ng/ml M-CSF only (for macrophage cultures) or 25 ng/ml M-CSF plus 
100 ng/ml RANKL (for osteoclast cultures) and cultured for 5 days as described above. For Western Blot analysis, 
BMDM cells were seeded in 6-well plates at 5 × 105 cells per well in medium supplemented with 25 ng/ml M-CSF 
and cultured for 3 days.
Western Blotting. Whole cell lysates (WCL) were prepared by lysing cells in lysis buffer [50 mM Tris pH 
7.6, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 1 mM sodium ortho-vanadate, 5 mM sodium 
fluoride, 50 µg/mL phenylmethylsulfonyl fluoride (PMSF), protease inhibitor cocktail mix 1 (Calbiochem) and 
PhosSTOP (Roche)]. WCL were resolved by SDS-PAGE on 4–12% gradient polyacrylamide gels (Invitrogen) 
at 180 V for 1 hr and transferred electrophoretically by wet transfer system onto PVDF membrane (Milipore) 
at 100 V for 1 hr. Blots were blocked for 1 hr with 5% skimmed milk, rinsed and probed with the required pri-
mary antibody (diluted in 5% BSA, 0.1% Tween-20 containing TBS and 0.05% sodium azide) overnight at 4 °C. 
Following incubation with appropriate horseradish peroxidase-conjugated secondary antibody (Cell Signalling, 
7076 or 7074, 1:5000) (in 5% skimmed milk), bands were visualised using Bio-RAD ChemiDoc™ Imaging 
System and software. Antibodies used were: ERK5 (Cell Signalling, 3372, 1:1000) and HSC70 (B-6) (Santa Cruz 
Biotechnology, sc-7298, 1:1000). Densitometry was performed using Image J software.
Statistical analysis. Statistical analyses (t-test; ANOVA, using Dunnett’s post-hoc test) were performed 
using GraphPad Prism v7.02 or SPSS v21 software. For all graphs, mean ± SEM (error bars) are presented.
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